within Pharmacolibrary.Drugs.S_SensoryOrgans.S01B_AntiinflammatoryAgents.S01BC10_Nepafenac;

model Nepafenac
  extends Pharmacolibrary.Drugs.ATC.S.S01BC10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01BC10</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) used as an ophthalmic solution to treat pain and inflammation associated with cataract surgery. It is a prodrug rapidly converted to amfenac in ocular tissues and is approved for topical ophthalmic use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult human eyes after single or multiple topical ophthalmic administrations (0.1% nepafenac solution, typical clinical dose). The presented data pertain to the conversion to amfenac (active metabolite) in the aqueous humor.</p><h4>References</h4><ol><li><p>Jones, BM, &amp; Neville, MW (2013). Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery. <i>The Annals of pharmacotherapy</i> 47(6) 892–896. DOI:<a href=\"https://doi.org/10.1345/aph.1R757\">10.1345/aph.1R757</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23715071/\">https://pubmed.ncbi.nlm.nih.gov/23715071</a></p></li><li><p>Sheppard, JD, et al., &amp; Jasek, MC (2018). In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits. <i>Ophthalmology and therapy</i> 7(1) 157–165. DOI:<a href=\"https://doi.org/10.1007/s40123-018-0130-1\">10.1007/s40123-018-0130-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29761367/\">https://pubmed.ncbi.nlm.nih.gov/29761367</a></p></li><li><p>Sheppard, JD, et al., &amp; Jasek, MC (2019). Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits. <i>Ophthalmology and therapy</i> 8(2) 347–348. DOI:<a href=\"https://doi.org/10.1007/s40123-019-0172-z\">10.1007/s40123-019-0172-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30783961/\">https://pubmed.ncbi.nlm.nih.gov/30783961</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Nepafenac;
